Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 16 |
| Active Pipeline (Recruiting Now) | 6 (1) |
| Completed vs Stopped Early | 5 / 1 (6.3%) |
| Median Closed Actual Enrollment | 156 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| The first affiliated hospital of Zhengzhou University | Zhengzhou, Henan | 5 |
| Zhejiang Provincial People's Hospital | Hangzhou, Zhejiang | 4 |
| The First Hospital of Jilin University | Changchun, Jilin | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06680921 | A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) | Phase III | ACTIVE NOT RECRUITING |
| NCT04908787 | A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer | Phase III | COMPLETED |
| NCT06010693 | A Study of Daridorexant in Chinese Patients With Insomnia Disorder | Phase III | COMPLETED |
| NCT05506176 | A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With | Phase II/III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Jiangsu Simcere Pharmaceutical Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.